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Introduction
Visceral leishmaniasis, also known as Kalazar, is 
an anthropozoonosis caused by a protozoan belong-
ing to the order Kinetoplastida, family Trypanoso-
matidae and genus Leishmania, of which Leishmania 
(Leishmania) chagasi (Cunha and Chagas, 1937) is the 
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Aiming to assess the efficacy of the treatment, to verify the occurrence of possible disease relapses and to search for 
the presence of parasites after the treatment, seven dogs naturally infected by Leishmania sp., were submitted to a 
treatment with meglumine antimoniate and allopurinol. For this, lymph node and bone marrow aspiration biopsies 
were carried out at seven moments. After the end of the six-month observation period all dogs were submitted to 
euthanasia. Then, spleen and liver “imprints” and in vitro cultures were carried out to search for amastigote forms 
of the parasite. All animals presented remission of the symptoms and during all the observation period no dog 
presented relapse of the disease, although amastigote forms of the parasite were observed in two of the animals at the 
end of the experiment. Thus, it was possible to conclude that the treatment promotes clinical healing but it does not  
eliminate the parasites completely.
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Resumo
Com objetivo de avaliar a eficácia do tratamento, verificar a ocorrência de possíveis recidivas da doença e pesquisar 
a presença de parasitas após a realização do tratamento, foram utilizados sete cães naturalmente infectados por 
Leishmania sp., submetidos a tratamento com antimoniato de meglumina e alopurinol. Para tanto, foram realizadas 
punções biópsias aspirativas de linfonodos e de medula óssea em sete momentos. Após o término dos seis meses de 
observação, todos os cães foram submetidos à eutanásia e realizados “imprints” e cultivo in vitro do baço e fígado para 
a pesquisa de formas amastigotas. Todos os animais apresentaram remissão dos sintomas e durante todo o período de 
observação nenhum cão apresentou recidiva da doença apesar de ter sido observada a presença de formas amastigotas 
do parasita em dois animais, ao término do experimento. Desta forma, foi possível concluir que o tratamento promove 
a cura clínica, entretanto não elimina completamente os parasitas.
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species found in Brazil1,2,3,4. Leishmania (Leishmania) 
chagasi has already been identified in humans, dogs, 
cats, wild canids, marsupials and rodents2,3. In the
 domestic environment, the dog is considered the 
main epidemiological reservoir, which makes con-
trolling the disease difficult. From the epidemiologi-
cal point of view, canine kalazar is considered more 
important than the human disease because besides 
being more prevalent, the canine enzootic disease has 
preceded the occurrence of human cases, with a great 
contingent of infected animals with skin parasitism 
serving as source of infection for the vector insects2,5.
The transmission among vertebrate hosts occurs 
through the bite of a hematophagous phlebotomine5,6. 
Leishmania (Leishmania) chagasi may attack practi-
cally all body systems, leading to a great variety of un-
specific symptoms in the dog1,7,8,9. 
The safest form of diagnosis of visceral leishmaniasis 
is the direct observation of amastigote forms of the par-
asite in lymph node and bone marrow smears, spleen 
aspirates, liver biopsies and blood smears1,7. This is the 
simplest method and the one most used in veterinary 
clinics. The technique, if carried out appropriately, is 
quick and little traumatic7. The specificity of this meth-
od is virtually 100%, but depending on the time spent 
looking for the parasite the sensitivity becomes 80% at 
the most in symptomatic dogs and lower in asymptom-
atic dogs10. According to some authors, the sensitivity 
of the method varies, ranging from 50 to 83% for bone 
marrow samples, from 30 to 85% for lymph node cy-
tology7,11, and from 71% to 91% when both tissues are 
associated11. The number of amastigotes detected in 
aspirates varies considerably, and few parasites are evi-
denced in treated animals1. 
Pentavalent antimonials, particularly meglumine an-
timoniate, are the medications of choice in the treat-
ment of human visceral leishmaniasis, and have been 
used as treatment protocol for dogs in Europe12,13,14,15. In 
Brazil prophylactic control program for visceral leish-
maniasis includes the elimination of infected dogs5.   
The mechanism of action of these medications 
have not been completely established, but it is known 
that they act on the amastigote forms of the parasite, 
blocking their metabolism by inhibiting the glycolitic 
activity and the oxidation pathway of fatty acids, be-
ing, thus, considered leishmanicidal5,12. Pentavalent 
antimonials cause reduction of the symptoms and, in 
some cases, even clinical cure of the dogs13,15,16,17,18,19,20. 
Nonetheless, there is evidence that they do not pro-
mote the complete elimination of the parasites, thus 
enabling treated dogs to remain as reservoir of the 
disease14,16,19,20.  
Another medication widely used in combination 
with pentavalent antimonials is allopurinol, a low 
cost drug to be administered orally with few side ef-
fects6,10,12,20. It is believed that the mechanism of action 
of allopurinol is the formation of a highly toxic ATP 
analog, which is incorporated within the RNA of the 
parasite, thus inhibiting its protein synthesis11. As it 
is a leishmaniostatic agent, its action is greater when 
combined with the use of other medications. Thus, it 
has been used to maintain treatment after the use of 
meglumine antimoniate, with reduction of the rates of 
relapse of the disease17,18.
There are few reports in the literature about the 
follow-up of animals infected by Leishmania (Leish-
mania) chagasi submitted to treatment. Hence, the 
present study aimed to assess the efficacy of the 
protocol in the treatment of canine visceral leish-
maniasis, to verify the occurrence of relapses, and 
to evaluate the presence of parasites in the treated 
dogs to know whether they remained or not carri-
ers of the disease.
Material and Method
Seven pet dogs naturally infected by Leishma-
nia sp., five males (71%) and two females (29%), of 
various breeds, with ages ranging from ten months 
to six years, were used in this study, conducted in 
2003. Six animals were symptomatic and one asymp-
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tomatic (Table 1). The diagnosis of the disease was 
reached by the identification of amastigote forms of 
Leishmania sp. in the cytological examination of 
lymph node and bone marrow aspirates and con-
firmed by enzyme immune assay (ELISA) which 
cut-off was determined as 0.270. After the confirma-
tion of the diagnosis, all animals were submitted to a 
complete clinical examination, and the data were col-
lected in individual charts. During the whole experi-
mental period the dogs were fed with balanced com-
mercial dog food (Selection Special Croc Evolution 
- Royal Canin), were given water ad libitum, wore 
deltamethrin antiparasitic collar (Scalibor - Inter-
vet Production S.A.), and were kept in a screened 
kennel to avoid reinfection.
All the animals were submitted to a treatment 
with 75 mg/kg subcutaneous meglumine antimoni-
ate (Glucantime - Aventis Pharma Ltda) every 12 
hours for 21 days, combined with a 10 mg/kg oral 
dose of allopurinol (generic – Hexal Ltda) every 12 
hours for 180 days and were followed-up through 
a period of 180 days to verify the occurrence of 
relapses. Food and water ingestion was evaluated 
and the animals were submitted daily to a physical 
examination, and monthly to urinalysis and hae-
mathological analysis, which included a complete 
blood count (erythrogram, leukogram and qualita-
tive platelet count).
Lymph node and bone marrow aspiration biopsies 
were carried out to search for the parasite in seven mo-
ments: M1- before the beginning of the treatment; M2- 
30 days; M3- 60 days; M4- 90 days; M5- 120 days; M6- 
150 days and M7- 180 days after the beginning of the 
treatment. The collection of bone marrow was done, 
under anesthesia, with a 40x16 mm needle for bone 
marrow aspiration biopsy, through a prick in the crest of 
the ilium of the animals, and the popliteal lymph node 
aspiration biopsy was performed with a 25x7 mm needle 
and a 10 ml syringe. 
After lymph node and bone marrow aspiration bi-
opsies, 180 days after the beginning of the treatment, 
all dogs were euthanized with 15 mg/kg intravenous 
sodium pentobarbital (Hypnol 3% - Fontoveter – 
Itapira, SP), followed by 10 ml potassium chloride 
(19.1% potassium chloride - Darrow – Rio de Janei-
ro, RJ). Spleen and liver imprints and in vitro culture 
were performed from tissues collected at necropsy. 
The slides were stained with rapid hematological 
staining and observed under optical microscope at a 
100x magnification to search for amastigote forms of 
the parasite in the smear.
The samples obtained from the spleen and the liv-
er were incubated in RPMI-1640 media (SIGMA) 
supplemented with 10% fetal bovine serum (v/v), 
antibiotics (100 IU / ml penicillin and 100 µg / ml 
streptomycin), hemin (0.01 g/l ), folic acid (0.02 g/l) 
and 2% human male urine, at 26 °C for 30 days. The 
cultures were observed under optical microscope to 
search for promastigote forms of the parasite once a 
week for 30 days.
Results
All dogs had positive serology by enzyme im-
mune assay (ELISA) with cut-off ranging from 
0.410 to 0.886. The six symptomatic dogs present-
ed: weight loss, limphadenomegaly, splenomegaly, 
onychogryphosis, alopecia and skin lesions charac-
terized basically by cutaneous ulcers. Some of them 
(42.9%) had proteinuria, granular casts and renal 
cells in urinary sediment, indicating renal lesions, 
and (42.9%) had anaemia, confirmed by the eryth-
rogram (Table 1). The other one dog were asymp-
tomatic, with normal urinalysis and haematho-
logical analysis, although it had amastigote forms 
of Leishmania visualized through lymph node and 
bone marrow aspiration biopsies.
None of the dogs had side effects with the treat-
ment. All six symptomatic dogs presented remis-
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sion of the symptoms within 60 days after the be-
ginning of the treatment, accompanied by restora-
tion to normal of urinary and haemathological pro-
files and all animals remained asymptomatic until 
the end of the experiment. During all the observa-
tion period amastigote forms of the parasite were 
not identified in any of the animals through bone 
marrow and lymph node aspiration biopsies. When 
spleen and liver “imprints” and in vitro cultures 
were carried out at the end of the experiment, the 
presence of parasites was verified in two (28.5%) of 
the seven dogs (dogs 3 and 4). In dog 3, they were 
present in both “imprints” (spleen and liver), and 
in dog 4 only in the spleen (Table 2). 
Discussion and Conclusion
All animals submitted to the treatment with me-
glumine antimoniate and allopurinol presented re-
mission of the symptoms, which corroborates the 
findings of Alvar et al.16, Ginel et al.17, Denerolle and 
Bourdoiseau18, Riera et al.19 and Baneth and Shaw20, 
who affirmed that the treatment with meglumine 
antimoniate promotes the clinical cure of the dogs. 
During the whole period of observation none of the 
animals presented relapses, in accordance with the 
findings of Ginel et al.17, who reported that the inter-
mittent administration of allopurinol, after the initial 
treatment with meglumine antimoniate, is efficient to 
hinder the occurrence of clinical relapses. 
During the whole period of 180 days the presence of 
amastigote forms of the parasite was not evidenced in 
none of the treated animals, giving the impression the 
treatment had provided a parasitological cure. How-
ever, spleen and liver “imprints” and in vitro culture, 
carried out at the end of the experiment, revealed the 
presence of parasites in two dogs. Thus, it is evidenced 
that lymph node and bone marrow aspiration biopsies 
are not a 100% efficient and safe method to confirm 
parasitological cure in dogs submitted to treatment, 
as the identification of the parasite was only possible 
through the investigation of organs such as the liver 
and the spleen. These data disagree with the findings 
of Koutinas et al.11, which affirmed that the sensitivity 
of the lymph node and bone marrow cytological ex-
amination varied from 71% to 91%. On the other hand, 
they confirm the reports of Kontos and Koutinas1 and 
Slappendel and Ferrer10, who affirmed that the cyto-
logical examination presented low sensitivity and that, 
in asymptomatic animals, submitted to treatments, few 
parasites were identified. Roura, Sánchez and Ferrer21 
verified that in 15 treated dogs no parasite was ob-
served in the cytological examination of the bone mar-
row, while seven animals presented positivity when the 
PCR technique was carried out. Therefore, we cannot 
affirm that the agent was definitively eliminated in the 
five dogs that did not present parasites at the end of the 
experiment. In spite of the clinical improvement ob-
Dogs Pre-treatment
180 days after the beginning of the treatment (M6) 







1 Symptomatic Asymptomatic - - - -
2 Symptomatic Asymptomatic - - - -
3 Symptomatic Asymptomatic - - + +
4 Asymptomatic Asymptomatic - - + -
5 Symptomatic Asymptomatic - - - -
6 Symptomatic Asymptomatic - - - -
7 Symptomatic Asymptomatic - - - -
Table 2 - Clinical status and parasitological evaluation of the dogs with visceral leishmaniasis 180 days after the beginning 
of the treatment with meglumine antimoniate and allopurinol - Araçatuba – SP - 2009
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served in the treated animals, the combination of me-
glumine antimoniate and allopurinol was not able to 
eliminate the parasite from all dogs, which makes this 
treatment protocol not recommended, particularly in 
endemic areas, because the animals remain a source of 
infection for humans and for other dogs.
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